Shares of OpGen, Inc. (NASDAQ:OPGN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $1.50 for the company and are expecting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 166 out of 265 based on the ratings given to its competitors.

OPGN has been the subject of several recent research reports. Zacks Investment Research lowered shares of OpGen from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. HC Wainwright reiterated a “buy” rating and set a $1.00 target price on shares of OpGen in a report on Monday, September 11th.

OpGen (NASDAQ OPGN) traded up $0.01 during mid-day trading on Friday, hitting $0.23. OpGen has a 12 month low of $0.20 and a 12 month high of $3.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.13 and a current ratio of 1.23.

An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. purchased a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned approximately 2.72% of OpGen as of its most recent SEC filing. Hedge funds and other institutional investors own 12.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/10/opgen-inc-opgn-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.